首个白血病治疗基因疗法在美获批_时事

首个白血病治疗基因疗法在美获批

Kymriah was approved by the US Food and Drug Administration for children and young adult patients up to age 25 with a form of acute lymphoblastic leukemia (ALL).

Kymriah获得美国食品药品监督管理局批准，用于治疗25岁以下的急性淋巴性白血病患者。

To qualify for treatment, patients must have B-cell precursor ALL that is refractory, or the patient has relapsed at least twice.

只有患有难治型B细胞急性淋巴细胞白血病的患者或复发两次以上的患者才能获得治疗资格。

The FDA described the approval as "a historic action" and a "new approach to the treatment of cancer and other serious and life-threatening diseases," said a statement.

一份声明指出，美国食品药品监督管理局将这次批准形容为“一次历史性的举动”和“治疗癌症及其他严重或致命疾病的新途径”。

如何治疗

The treatment is not a pill or a form of chemotherapy, which can weaken the body's natural defenses.

这种治疗手段并不使用药剂或化疗，不会削弱人体自身的抵抗力。

Instead, it harnesses a patient's own immune cells, called T-cells and white blood cells, and trains them to recognise and fight cancer.

该疗法使用患者自身的免疫细胞——T细胞和白细胞，并训练细胞识别并对抗癌症。

The patient's immune cells are removed with a special blood filtration process, sent to a lab, and genetically encoded to be able to hunt down cancer cells.